Cowen initiates coverage on UroGen Pharma (NASDAQ: URGN) with a Outperform rating.Analyst Dr. Boris Peaker likes the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE